PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
33512458-7	2021	Drug sensitivity was associated with the leukemia genotype, with the PARP inhibitor talazoparib and the demethylating agent decitabine efficacious in Trp53/Bcor mutant AEL, CDK7/9 inhibitors in Trp53/Bcor/Dnmt3a mutant AEL and gemcitabine and bromodomain inhibitors in NUP98-KDM5A leukemia.	Decitabine	124-134	cyclin-dependent kinase 7	Mus musculus	173-179
12748294-1	2003	The histidine triad (HIT) protein Hint has been found to associate with mammalian Cdk7, as well as to interact both physically and genetically with the budding yeast Cdk7 homologue Kin28.	Histidine	4-13	cyclin-dependent kinase 7	Mus musculus	166-170
34717033-0	2021	CDK7 is essential for spermatogenesis by regulating RA signaling pathways and the STAT3 molecular pathway.	Radium	52-54	cyclin-dependent kinase 7	Mus musculus	0-4
34717033-4	2021	Inhibition of CDK7 activity affected spermatogonia proliferation and differentiation, and we found that CDK7 regulates RA-mediated c-KIT expression to play a role in spermatogonia.	Radium	119-121	cyclin-dependent kinase 7	Mus musculus	104-108
34717033-5	2021	Then, we demonstrated that inhibition of CDK7 affected meiosis initiation, DNA repair and synaptonemal complex formation in meiosis progression, and CDK7 played this role by regulating RA-mediated STRA8 and REC8 signaling pathways.	Radium	185-187	cyclin-dependent kinase 7	Mus musculus	41-45
34717033-5	2021	Then, we demonstrated that inhibition of CDK7 affected meiosis initiation, DNA repair and synaptonemal complex formation in meiosis progression, and CDK7 played this role by regulating RA-mediated STRA8 and REC8 signaling pathways.	Radium	185-187	cyclin-dependent kinase 7	Mus musculus	149-153
34726887-0	2022	Discovery of SY-5609: A Selective, Noncovalent Inhibitor of CDK7.	SY-5609	13-20	cyclin-dependent kinase 7	Mus musculus	60-64
34726887-2	2022	This report describes the discovery of SY-5609, a highly potent (sub-nM CDK7 Kd) and selective, orally available inhibitor of CDK7 that entered the clinic in 2020 (ClinicalTrials.gov Identifier: NCT04247126).	SY-5609	39-46	cyclin-dependent kinase 7	Mus musculus	72-76
34726887-2	2022	This report describes the discovery of SY-5609, a highly potent (sub-nM CDK7 Kd) and selective, orally available inhibitor of CDK7 that entered the clinic in 2020 (ClinicalTrials.gov Identifier: NCT04247126).	SY-5609	39-46	cyclin-dependent kinase 7	Mus musculus	126-130
34726887-5	2022	The development candidate SY-5609 displays potent inhibition of CDK7 in cells and demonstrates strong efficacy in mouse xenograft models when dosed as low as 2 mg/kg.	SY-5609	26-33	cyclin-dependent kinase 7	Mus musculus	64-68
34004188-3	2021	Meanwhile, genetic or pharmacological inhibition of CDK7 ameliorated the severity of psoriasis in imiquimod-induced psoriasis-like mouse model and suppressed CD4+ T cell activation as well as Th17/Th1 cell differentiation in vivo and in vitro.	Imiquimod	98-107	cyclin-dependent kinase 7	Mus musculus	52-56
32447197-3	2020	Herein, we discovered coumarin derivative 30i as a potent CDK9 inhibitor with high selectivity (8300-fold over CDK7).	coumarin	22-30	cyclin-dependent kinase 7	Mus musculus	111-115
33244299-3	2020	Analyses of control and CAPE-induced neurodifferentiated cells revealed: (i) modulation of several key proteins (NF200, MAP-2, NeuN, PSD95, Tuj1, GAP43, and GFAP) involved in neurodifferentiation process; and (ii) attenuation of neuronal stemness (HOXD13, WNT3, and Msh-2) and proliferation-promoting (CDC-20, CDK-7, and BubR1) proteins.	caffeic acid phenethyl ester	24-28	cyclin-dependent kinase 7	Mus musculus	310-315
32447197-4	2020	Binding mode analysis illustrated that the substituent coumarin moiety is a critical group for CDK9 selectivity by occupying a flexible hinge/alphaD region, which is sterically hindered in other CDKs.	coumarin	55-63	cyclin-dependent kinase 7	Mus musculus	195-199
31506280-0	2019	Tumors with TSC mutations are sensitive to CDK7 inhibition through NRF2 and glutathione depletion.	Glutathione	76-87	cyclin-dependent kinase 7	Mus musculus	43-47
31883968-3	2020	Using a selective CDK7 inhibitor, YKL-5-124, we demonstrated that CDK7 inhibition predominately disrupts cell-cycle progression and induces DNA replication stress and genome instability in small cell lung cancer (SCLC) while simultaneously triggering immune-response signaling.	YKL-5-124	34-43	cyclin-dependent kinase 7	Mus musculus	18-22
31883968-3	2020	Using a selective CDK7 inhibitor, YKL-5-124, we demonstrated that CDK7 inhibition predominately disrupts cell-cycle progression and induces DNA replication stress and genome instability in small cell lung cancer (SCLC) while simultaneously triggering immune-response signaling.	YKL-5-124	34-43	cyclin-dependent kinase 7	Mus musculus	66-70
31506280-5	2019	Mechanistic studies revealed that CDK7 inhibition markedly reduces glutathione levels and increases reactive oxygen species due to reduced expression of NRF2 and glutathione biosynthesis genes.	Glutathione	67-78	cyclin-dependent kinase 7	Mus musculus	34-38
31506280-5	2019	Mechanistic studies revealed that CDK7 inhibition markedly reduces glutathione levels and increases reactive oxygen species due to reduced expression of NRF2 and glutathione biosynthesis genes.	Oxygen	109-115	cyclin-dependent kinase 7	Mus musculus	34-38
31506280-5	2019	Mechanistic studies revealed that CDK7 inhibition markedly reduces glutathione levels and increases reactive oxygen species due to reduced expression of NRF2 and glutathione biosynthesis genes.	Glutathione	162-173	cyclin-dependent kinase 7	Mus musculus	34-38
31526394-0	2019	Transcriptional inhibition by CDK7/9 inhibitor SNS-032 abrogates oncogene addiction and reduces liver metastasis in uveal melanoma.	N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide	47-54	cyclin-dependent kinase 7	Mus musculus	30-36
31526394-4	2019	We hypothesized that inhibition of transcription by cyclin-dependent kinase 7/9 (CDK7/9) inhibitor SNS-032 diminished liver metastasis by abrogating the putative oncogenes in charge of colonization, stemness, cell motility of UM cells in host liver microenvironment.	N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide	99-106	cyclin-dependent kinase 7	Mus musculus	52-79
30473182-6	2019	The 4-nitroquinoline 1-oxide (4NQO)-induced OSCC mouse model was developed to monitor CDK7 expression during cancer initiation and progression.	4-Nitroquinoline-1-oxide	4-28	cyclin-dependent kinase 7	Mus musculus	86-90
30473182-6	2019	The 4-nitroquinoline 1-oxide (4NQO)-induced OSCC mouse model was developed to monitor CDK7 expression during cancer initiation and progression.	4-Nitroquinoline-1-oxide	30-34	cyclin-dependent kinase 7	Mus musculus	86-90
23765726-6	2013	This resulting DeltaCAK acted as a dominant negative to inhibit the growth and metastasis of different leukemic myeloblasts, with or without RA resistance, by concurrently suppressing CAK and TFIIH kinase activities to inhibit cell cycle and gene transcription.	Tretinoin	141-143	cyclin-dependent kinase 7	Mus musculus	20-23
25978317-0	2015	Interaction of cCMP with the cGK, cAK and MAPK Kinases in Murine Tissues.	Cyclic CMP	15-19	cyclin-dependent kinase 7	Mus musculus	34-37
25978317-2	2015	These purine cyclic nucleotides activate cAK and cGK, respectively.	purine	6-12	cyclin-dependent kinase 7	Mus musculus	41-44
25978317-2	2015	These purine cyclic nucleotides activate cAK and cGK, respectively.	Nucleotides, Cyclic	13-31	cyclin-dependent kinase 7	Mus musculus	41-44
25978317-9	2015	Cyclic nucleotide-dependent protein kinases (cAK, cGKI and cGKII) in WT tissue lysates were stimulated by cCMP.	Cyclic CMP	106-110	cyclin-dependent kinase 7	Mus musculus	45-48
25978317-18	2015	Hence, cCMP could potentially act as a second messenger in the cAK/cGK and MAPK signaling pathways and play an important role in physiological processes of the jejunum and lung.	Cyclic CMP	7-11	cyclin-dependent kinase 7	Mus musculus	63-66
22006019-6	2011	The biological importance of three of these kinases (cyclin-dependent kinase 7 [CDK7], Plk1, and KPCD1) in the protection against cisplatin-induced cytotoxicity was demonstrated by small interfering RNA (siRNA)-mediated knockdown.	Cisplatin	130-139	cyclin-dependent kinase 7	Mus musculus	53-78
22447844-0	2012	Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor alpha and bcr-abl oncogene addiction in malignant hematologic cells.	N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide	38-45	cyclin-dependent kinase 7	Mus musculus	0-27
22447844-3	2012	The purpose of this study was to evaluate the strategy of shutting down the transcription and expression of FIP1-like-1 (FIP1L1)-PDGFRalpha and Bcr-Abl with SNS-032, an inhibitor of cyclin-dependent kinase 7 (CDK7) and CDK9 in phase I clinical trials.	N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide	157-164	cyclin-dependent kinase 7	Mus musculus	182-207
22447844-3	2012	The purpose of this study was to evaluate the strategy of shutting down the transcription and expression of FIP1-like-1 (FIP1L1)-PDGFRalpha and Bcr-Abl with SNS-032, an inhibitor of cyclin-dependent kinase 7 (CDK7) and CDK9 in phase I clinical trials.	N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide	157-164	cyclin-dependent kinase 7	Mus musculus	209-213
22006019-6	2011	The biological importance of three of these kinases (cyclin-dependent kinase 7 [CDK7], Plk1, and KPCD1) in the protection against cisplatin-induced cytotoxicity was demonstrated by small interfering RNA (siRNA)-mediated knockdown.	Cisplatin	130-139	cyclin-dependent kinase 7	Mus musculus	80-84
19621384-6	2010	When doxorubicin was administered 24 hr before zoledronic acid, tumors displayed decreased expression of CYCLINS E1, B, D1 and D3 as well as CDK2, CDC2, CDK4 and CDK7, indicative of cell-cycle inhibition.	Doxorubicin	5-16	cyclin-dependent kinase 7	Mus musculus	162-166
21487803-8	2011	In comparison to roscovitine, these compounds showed an increased potency to inhibit Cdk2, Cdk5, Cdk7, and Cdk9.	Roscovitine	17-28	cyclin-dependent kinase 7	Mus musculus	97-101
20231280-2	2010	As a component of TFIIH, Cdk7 phosphorylates serines 5 and 7 of the carboxyl-terminal domain of RNA polymerase II and can also directly phosphorylate transcription factors to regulate gene expression.	Serine	45-52	cyclin-dependent kinase 7	Mus musculus	25-29
19616371-4	2010	Xylocydine also strongly inhibits the activity of Cdk7 and Cdk9, in vitro as well as in cell cultures, that is temporally associated with apoptotic cell death in xylocydine-induced HCC cells.	4-amino-6-bromo-7-(xylofuranosyl)pyrrolo(2,3-d)pyrimidine-5-carboxamide	0-10	cyclin-dependent kinase 7	Mus musculus	50-54
19616371-4	2010	Xylocydine also strongly inhibits the activity of Cdk7 and Cdk9, in vitro as well as in cell cultures, that is temporally associated with apoptotic cell death in xylocydine-induced HCC cells.	4-amino-6-bromo-7-(xylofuranosyl)pyrrolo(2,3-d)pyrimidine-5-carboxamide	162-172	cyclin-dependent kinase 7	Mus musculus	50-54
19616371-5	2010	This is associated with inhibition of phosphorylation of RNA polymerase II at serine residues 5 and 2, which are targets of Cdk7 and Cdk9, respectively.	Serine	78-84	cyclin-dependent kinase 7	Mus musculus	124-128
19553566-12	2009	Together, our data indicate that roscovitine abolishes LPS-induced (*)NO production in macrophages by suppressing nuclear factor-kappaB activation and BH(4) biosynthesis, which might be mediated by CDK1, CDK5, and CDK7.	Roscovitine	33-44	cyclin-dependent kinase 7	Mus musculus	214-218
19723896-3	2009	We tested whether the small molecule Cdk inhibitor SNS-032 (formerly BMS-387032), which targets Cdk2, Cdk7, and Cdk9, can prevent intestinal tumorigenesis in mouse models.	N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide	51-58	cyclin-dependent kinase 7	Mus musculus	102-106